Mundipharma International Limited - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 71

Mundipharma International Limited – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Mundipharma International Limited - Product Pipeline Review - 2012” provides data on the Mundipharma International Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Mundipharma International Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Mundipharma International Limited and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Mundipharma International Limited - Brief Mundipharma International Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Mundipharma International Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Mundipharma International Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Mundipharma International Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Mundipharma International Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Mundipharma International Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Mundipharma International Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Mundipharma International Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Mundipharma International Limited and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Mundipharma International Limited; Mundipharma International Limited - Key Therapeutics; Mundipharma International Limited - Pipeline Overview and Promising Molecules; Mundipharma International Limited - News; Mundipharma International Limited - Latest Updates; Mundipharma International Limited - Pipeline; Mundipharma International Limited - Discontinued/Dormant Projects

List of Tables
List of Figures
Mundipharma International Limited Snapshot
Mundipharma International Limited Overview
Key Information
Key Facts
Mundipharma International Limited – Research and Development Overview
Key Therapeutic Areas
Mundipharma International Limited – Pipeline Review
Pipeline Products by Stage of Development
Mundipharma International Limited – Pipeline Products Glance
Mundipharma International Limited – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Mundipharma International Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Mundipharma International Limited – Drug Profiles
Bendamustine Hydrochloride
Product Description
Mechanism of Action
R&D Progress
Flutiform
Product Description
Mechanism of Action
R&D Progress
Forodesine
Product Description
Mechanism of Action
R&D Progress
Norspan
Product Description
Mechanism of Action
R&D Progress
Sevre-Long
Product Description
Mechanism of Action
R&D Progress
Mundipharma International Limited – Pipeline Analysis
Mundipharma International Limited – Pipeline Products by Therapeutic Class
Mundipharma International Limited – Pipeline Products By Target
Mundipharma International Limited – Pipeline Products by Route of Administration
Mundipharma International Limited – Pipeline Products By Mechanism of Action
Mundipharma International Limited – Recent Pipeline Updates
Mundipharma International Limited - Dormant Projects
Mundipharma International Limited – Company Statement
Mundipharma International Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Mundipharma International Limited - Key Manufacturing Facilities
Financial Deals Landscape
Mundipharma International Limited, Deals Summary
Mundipharma International Limited, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Allos Therapeutics Enters Into Collaboration And Licensing Agreement With Mundipharma International For FOLOTYN
Helsinn Healthcare Enters Into Licensing Agreement With Rafa Labs
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA
Infinity Pharma Extends Co-Development Agreement With Mundipharma
Infinity Pharma Extends Its Collaboration Agreement With Mundipharma International
Horizon Pharma Enters Into Distribution Agreement With Mundipharma International Corporation For LODOTRA
Mundipharma International And Purdue Pharma Exercises Rights To Infinity's FAAH Program
Mundipharma Enters Into Agreement With Nitec Pharma
Mundipharma Enters Into Agreement With Novelos Therapeutics
Infinity Pharma Enters Into Collaboration Agreement With Mundipharma And Purdue Pharma
Mundipharma Enters Into Agreement With Purdue Pharma
Hisamitsu Pharma Enters Into An Agreement With Mundipharma
Sosei Enters Into An Agreement With Mundipharma
Mundipharma Enters Into Agreement With Grunenthal
Mundipharma Enters Into Agreement With BioCryst Pharma
SkyePharma Enters Into Agreement With Mundipharma
Licensing Agreements
Helsinn Healthcare Enters Into Licensing Agreement With MundiPharma
Mundipharma Enters Into License Agreement With Astellas Deutschland
Mundipharma Enters Into Licensing Agreement With SkyePharma
Sinclair Enters Into Licensing Agreement With Rafa Labs
Asset Transactions
Sosei Group Reacquires Rights To AD923 From Mundipharma
Skyepharma Acquires DepoBupivacaine Rights From Mundipharma International
Acquisition
Mundipharma International Acquires Clinical Designs From Abingworth Management
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Mundipharma International Limited, Key Information
Mundipharma International Limited, Key Facts
Mundipharma International Limited – Pipeline by Indication, 2012
Mundipharma International Limited – Pipeline by Stage of Development, 2012
Mundipharma International Limited – Filed, 2012
Mundipharma International Limited – Phase III, 2012
Mundipharma International Limited – Phase II, 2012
Mundipharma International Limited – Phase I, 2012
Mundipharma International Limited – Pipeline By Therapeutic Class, 2012
Mundipharma International Limited - Pipeline By Target, 2012
Mundipharma International Limited – Pipeline By Route of Administration, 2012
Mundipharma International Limited – Pipeline Products By Mechanism of Action, 2012
Mundipharma International Limited – Recent Pipeline Updates, 2012
Mundipharma International Limited - Dormant Developmental Projects,2012
Mundipharma International Limited, Other Locations
Mundipharma International Limited, Subsidiaries
Mundipharma International Limited, Deals Summary
Allos Therapeutics Enters Into Collaboration And Licensing Agreement With Mundipharma International For FOLOTYN
Helsinn Healthcare Enters Into Licensing Agreement With Rafa Labs
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA
Infinity Pharma Extends Co-Development Agreement With Mundipharma
Infinity Pharma Extends Its Collaboration Agreement With Mundipharma International
Horizon Pharma Enters Into Distribution Agreement With Mundipharma International Corporation For LODOTRA
Mundipharma International And Purdue Pharma Exercises Rights To Infinity's FAAH Program
Mundipharma Enters Into Agreement With Nitec Pharma
Mundipharma Enters Into Agreement With Novelos Therapeutics
Infinity Pharma Enters Into Collaboration Agreement With Mundipharma And Purdue Pharma
Mundipharma Enters Into Agreement With Purdue Pharma
Hisamitsu Pharma Enters Into An Agreement With Mundipharma
Sosei Enters Into An Agreement With Mundipharma
Mundipharma Enters Into Agreement With Grunenthal
Mundipharma Enters Into Agreement With BioCryst Pharma
SkyePharma Enters Into Agreement With Mundipharma
Helsinn Healthcare Enters Into Licensing Agreement With MundiPharma
Mundipharma Enters Into License Agreement With Astellas Deutschland
Mundipharma Enters Into Licensing Agreement With SkyePharma
Sinclair Enters Into Licensing Agreement With Rafa Labs
Sosei Group Reacquires Rights To AD923 From Mundipharma
Skyepharma Acquires DepoBupivacaine Rights From Mundipharma International
Mundipharma International Acquires Clinical Designs From Abingworth Management

List of Figures
Mundipharma International Limited – Pipeline by Indication, 2012
Mundipharma International Limited – Pipeline by Stage of Development, 2012
Mundipharma International Limited – Pipeline By Therapeutic Class, 2012
Mundipharma International Limited – Pipeline By Route of Administration, 2012
Mundipharma International Limited - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Alibaba.com Limited Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
• T-Mobile Germany: Mobile Broadband Case Study
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Oki Electric Industry Company, Limited
• Steria
• GOME Electrical Appliances Holding Limited
• Hutchison Whampoa Limited
• HP - Profile - Germany
• Logica - Profile - Germany
• SAP - Profile - Germany